Peripheral nerve disorders

Evidence-Based Neurology: Management of Neurological Disorders

Volumn , Issue , 2007, Pages 244-257

  Hughes, Richard ^a   Feldman, Eva L ^b   Bland, Jeremy D P ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

^c KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955435651     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988350.ch23     Document Type: Chapter

References (89)

1. Martyn CN, Hughes RAC. Epidemiology of peripheral neuropathy. J. Neurol. Neurosurg. Psychiatr. 1997; 62: 310-18.
2. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366: 1653-66.
3. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc. Natl. Acad. Sci. USA 2004; 101: 11404-9.
4. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.
5. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2002; 2: CD001798.
6. Greenwood RJ, Newsom Davis JM, Hughes RAC, Aslan S, Bowden AN, Chadwick DW, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 1: 877-9.
7. French Cooperative group in plasma exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann. Neurol. 1987; 22: 753-61.
8. French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann. Neurol. 1997; 41: 298-306.
9. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366: 1653-66.
10. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N. Engl. J. Med. 1992; 326: 1123-9.
11. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2006; 2: CD002063.
12. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996; 46: 100-3.
13. Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur. Neurol. 2001; 46: 107-9.
14. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
15. Nomura T, Hamaguchi K, Hattori T, Satou T, Mannen T, et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurological Therap. 2000; 18: 69-81.
16. Hughes RAC, Wijdicks E, Barohn RJ, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-40.
17. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2: 750-3.
18. Hughes RAC, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2006; 2: CD001446.
19. Bansal BC, Sood AK, Gupta AK, Yadav P. Role of steroids in the treatment of Guillain-Barré syndrome - a controlled trial. Neurol. India 2004; 34: 329-35.
20. Shukla SK, Agarwal R, Gupta OP, Pande G, Mamta S. Double blind control trial of prednisolone in Guillain-Barré syndrome - a clinical study. Clin.-India 1988; 52: 128-34.
21. Singh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome? J. Assoc. Phys. India 1996; 44: 22-4.
22. Van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J, van Doorn PA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363: 192-6.
23. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586-90.
24. Hughes RAC, Wijdicks E, Barohn RJ, Benson E, Cornblath DR, Hahn AF, et al. Supportive care for Guillain-Barré syndrome. Arch. Neurol. 2005; 62: 1194-8.
25. Ettayapuram V, Sunderrajan M, Davenport J. The Guillain-Barré syndrome: pulmonary-neurologic correlations. Medicine 1995; 64(5): 333-41.
26. Pontoppidan H, Geffin B, Lowenstein E. Acute respiratory failure in the adult. 2. N. Engl. J. Med. 1972; 287: 743-52.
27. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann. Neurol. 1988; 23: 347-53.
28. Holdgaard HO, Pedersen J, Jensen RH, Outzen KE, Midtgaard T, Johansen LV, et al. Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy. A clinical randomised study. Acta Anaesth. Scand. 1998; 42: 545-50.
29. Pfeiffer G, Schiller B, Kruse J, Netzer J. Indicators of dysautonomia in severe Guillain-Barré syndrome. J. Neurol. 1999; 246: 1015-22.
30. Flachenecker P, Hartung HP, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study. Brain 1997; 120(Pt 10): 1885-94.
31. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group [see comments]. N. Engl. J. Med. 1999; 341: 793-800.
32. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann. Surg. 1988; 208: 227-40.
33. Pandey CK, Bose N, Garg G, Singh N, Baronia A, Agarwal A, et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth. Analg. 2002; 95: 1719-23.
34. Tripathi M, Kaushik S. Carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit. Care. Med. 2000; 28: 655-8.
35. Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies IS, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology 2004; 63: 2393-5.
36. Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RDM, Hahn A, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J. Peripher. Nerv. Syst. 2005; 10: 220-8.
37. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2002; 1: CD002062.
38. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2004; 3: CD003906.
39. van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2002; 2: CD001797.
40. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 1994; 36: 838-45.
41. Hughes RAC, Bensa S, Willison HJ, van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001; 50: 195-201.
42. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2004; 4: CD003280.
43. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelinassociated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst. Rev. 2006; 2: CD002827.
44. van Schaik IN, Van den Berg LH, de Haan R. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst. Rev. 2005; 2: CD004429.
45. Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM. Immunosuppressive treatment for multifocal motor neuropathy. Cochrane Database Syst. Rev. 2005; 3:CD003217.
46. Peitersen E. Bell’s Palsy: the spontaneous course of 2, 500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol. (Stockh) 2002; 549(Suppl.): 4-30.
47. Salinas RA, Alvarez G, Ferreira J. Corticosteroids for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst. Rev. 2004; 4: CD001942.
48. Allen D, Dunn L. Aciclovir or valaciclovir for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst. Rev. 2004; 3: CD001869.
49. National Center for Chronic Disease Prevention and Health Promotion. Natl. Diab. Surveil. Syst. www.cdc.gov/diabetes/statistics.
50. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies. A statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-62.
51. Thomas PK. Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur. Neurol. 1999; 41(Suppl. 1): 35-43.
52. Gordois A, Schuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-5.
53. Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-53.
54. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293: 217-28.
55. Trotta D, Verrotti A, Salladini C, Chiarelli F. Diabetic neuropathy in children and adolescents. Pediatr. Diab. 2004; 5: 44-57.
56. Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab. Res. Rev. 2005; 21: 231-40.
57. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH for the EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005; 352: 341-50.
58. Writing Team for the Diabetes Control Trial. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
59. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann. Neurol. 1997; 42: 727-36.
60. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
61. Azad N, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, Nuttall FQ, Comstock JP, Sawin CT, Silbert C, Rubino FA. The effects of intensive glycaemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J. Diab. Complicat. 1999; 13: 307-13.
62. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med. Clin. N. Am. 2004; 88: 947-9.
63. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-73.
64. Simmons Z, Feldman EL. Treatment of diabetic neuropathy. In: Williams R, Herman W, Kinmonth A-L & Wareham NJ, eds., The Evidence Base for Diabetes Care. John Wiley & Sons, West Sussex, England, 2002: pp. 555-76.
65. Vincent AM, Feldman EL. New insights into the mechanisms of diabetic neuropathy. Rev. Endo. Metab. Dis. 2004; 5: 227-36.
66. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 2005; 20(3): CD005454 (Review).
67. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. 2005; 3: CD001133 (Review).
68. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 2004; 25: 612-28.
69. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Prevalence of carpal tunnel syndrome in a general population. JAMA 1999; 282: 153-8.
70. de Krom MC, Knipschild PG, Kester AD, Thijs CT, Boekkooi PF, Spaans F. Carpal tunnel syndrome, prevalence in the general population. J. Clin. Epidemiol. 1992; 45: 373-6.
71. Hakim AJ, Cherkas L, El Zayat S, MacGregor AJ, Spector TD. The genetic contribution to carpal tunnel syndrome in women: a twin study. Arthritis Rheum. 2002; 47(3): 275-9.
72. Padua L, Padua R, Aprile I, Pasqualetti P, Tonali P. Multiperspective follow-up of untreated carpal tunnel syndrome: a multicenter study. Neurology 2001; 56(11): 1459-66.
73. Anon. Practice parameter for carpal tunnel syndrome. Neurology 1993; 43: 2406-9.
74. Marshall S, Tardif G, Ashworth N. Local corticosteroid injection for carpal tunnel syndrome. Cochrane Database Syst. Rev. 2002; 4: CD001554.
75. O’Connor D, Marshall S, Massy-Westropp N. Non-surgical treatment (other than steroid injection) for carpal tunnel syndrome. Cochrane Database Syst. Rev. 2003; 1: CD003219.
76. Scholten RJPM, Gerritsen AAM, Uitdehaag BMJ, van Geldere D, de Vet HCW, Bouter LM. Surgical treatment options for carpal tunnel syndrome. Cochrane Database of Syst. Rev. 2004; 4: CD003905.
77. Verdugo RJ, Salinas RS, Castillo J, Cea JG. Surgical versus nonsurgical treatment for carpal tunnel syndrome. Cochrane Database Syst. Rev. 2002; 2: CD001552.
78. Gerritsen AAM, de Vet HCW, Scholten RJPM, Bertelsmann FW, de Krom MCTFM, Bouter LM. Splinting vs Surgery in the treatment of carpal tunnel syndrome: a randomised controlled trial. JAMA 2002; 288: 1245-51.
79. Ly-Pen D, Andreu JL, de Blas G, Sanchez-Olaso A, Millan I. Surgical decompression versus local steroid injection in carpal tunnel syndrome: a one-year, prospective, randomized, open, controlled clinical trial. Arthritis Rheum. 2005; 52: 612-19.
80. Hui AC, Wong S, Leung CH, Tong P, Mok V, Poon D, et al. A randomized controlled trial of surgery vs steroid injection for carpal tunnel syndrome. Neurology 2005; 64: 2074-8.
81. Demirci S, Kutluhan S, Koyuncuoglu HR, Kerman M, Heybeli N, Akkus S, et al. Comparison of open carpal tunnel release and local steroid treatment outcomes in idiopathic carpal tunnel syndrome. Rheumatol. Int. 2002; 22: 33-7.
82. Gokoglu F, Fndkoglu G, Yorgancoglu Z, Okumus M, Ceceli E, Kocaoglu S. Evaluation of iontophoresis and local corticosteroid injection in the treatment of carpal tunnel syndrome. Am. J. Phys. Med. Rehabil. 2005; 84: 92-6.
83. O’Gradaigh D, Merry P. Corticosteroid injection for the treatment of carpal tunnel syndrome. Ann. Rheum. Dis. 2000; 59: 918-19.
84. Assmus H. Korrektur und Rezidiveingriffe beim Karpaltunnelsyndrom. Bericht über 185 Nachoperationen. Nervenarzt 1996; 67: 998-1002.
85. Bland JDP. Do nerve conduction studies predict the outcome of carpal tunnel decompression? Muscle Nerve 2001; 24: 935-40.
86. Dammers JWHH, Veering MM, Vermeulen M. Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial. BMJ 1999; 319: 884-6.
87. Ozdogan H, Yazici H. The efficacy of local steroid injections in idiopathic carpal tunnel syndrome: a double-blind study. Br. J. Rheumatol. 1984; 23: 272-5.
88. Girlanda P, Dattola R, Venuto C, Mangiapane R, Nicolosi C, Messina C. Local Steroid treatment in idiopathic carpal tunnel syndrome: short and long term efficacy. J. Neurol. 1993; 240: 187-90.
89. Armstrong T, Devor W, Borschel L, Contreras R. Intracarpal steroid injection is safe and effective for short-term management of carpal tunnel syndrome. Muscle Nerve 2004; 29: 82-8.